Areas of Focus
Oncology and Inflammation
Our lead product candidate, PHP- 303 is an oral, once daily, potent, selective small molecule inhibitor of neutrophil elastase (NE) designed to inhibit the bioactive form of NE that Peak Bio is developing for the treatment of alpha1 anti-trypsin deficiency (AATD), a potentially life-threatening rare, genetic condition that results in severe debilitating diseases, including early-onset pulmonary emphysema. Also, PHP-303 is being explored in animal models of COVID-19-related acute respiratory distress syndrome (ARDS). Peak Bio has non-dilutive pre-clinical grant from the Department of Defense (DoD) to explore this indication.